Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 5/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 5/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20877646 | 0.98 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL20877621 | 0.98 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL25060963 | 0.98 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL19817529 | 0.98 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL3429112 | 0.96 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL24803728 | 0.88 | ADRA2A (0.31) | ADRA2AADRA2BADRA2C | |
| SCHEMBL25644900 | 0.86 | GRM1 (0.35) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL24997680 | 0.86 | GRM1 (0.38) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL25806779 | 0.82 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CHTR2AHTR2C | |
| SCHEMBL31003113 | 0.81 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | SCHRÖDINGER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | X4 PHARMACEUTICALS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-20230219962-A1 | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | MERCK SHARP & DOHME LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | MERCK SHARP & DOHME LLC (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230054854-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC | 2023-02-23 | — | — | US | disclosed |
| US-20090023774-A1 | Pyridine analogs as C5A antagonists | LACHANCE NICOLAS | 2009-01-22 | — | — | US | disclosed |
| US-20090023774-A1 | Pyridine analogs as C5A antagonists | LACHANCE NICOLAS | 2009-01-22 | — | — | US | disclosed |
| US-20090023774-A1 | Pyridine analogs as C5A antagonists | LACHANCE NICOLAS | 2009-01-22 | — | — | US | disclosed |
| US-7429666-B2 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | MERCK FROSST CANADA LTD. (CA) | 2008-09-30 | — | — | US | disclosed |
| US-7429666-B2 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | MERCK FROSST CANADA LTD. (CA) | 2008-09-30 | — | — | US | disclosed |
| US-7429666-B2 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | MERCK FROSST CANADA LTD. (CA) | 2008-09-30 | — | — | US | disclosed |
| CN-1968931-A | Pyridine analogs as C5A antagonists | MERCK FROSST CANADA LTD (CA) | 2007-05-23 | — | — | CN | disclosed |
| EP-1758865-A1 | PYRIDINE ANALOGS AS C5A ANTAGONISTS | Merck Frosst Canada Ltd. (CA) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005121095-A1 | PYRIDINE ANALOGS AS C5A ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277644-A1 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | MERCK FROSST CANADA LTD. (CA) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | ADRA2A 3031/4885ADRA2B 2417/4885ADRA2C 3163/4885 |
| US-20230219962-A1 | PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CELLULAR PROLIFERATIVE DISORDERS | DPYD, TYMP, TK1 | ADRA2A 4228/4885ADRA2B 3588/4885ADRA2C 3772/4885 |
| US-20050277644-A1 | antiinflammatory agents; N-[4-(Dimethylamino)benzyl]-N-(4-isopropylphenyl)-2-methoxy-5,6,7,8-tetrahydroquinoline-8-carboxamide | C5AR2, C5AR1, C3AR1 | ADRA2A 333/4885ADRA2B 351/4885ADRA2C 289/4885 |
| US-11780837-B2 | CXCR4 inhibitors and uses thereof | CXCR4, CXCL12, CXCR3 | ADRA2A 1101/4885ADRA2B 675/4885ADRA2C 1193/4885 |
| US-20240025898-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | ADRA2A 3784/4885ADRA2B 3948/4885ADRA2C 4322/4885 |
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | TLR7, MALT1, PNPO | ADRA2A 4680/4885ADRA2B 4249/4885ADRA2C 4431/4885 |
| US-20230054854-A1 | COMBINATIONS | WEE2, WEE1, BCL2 | ADRA2A 4304/4885ADRA2B 4399/4885ADRA2C 4418/4885 |
| US-20090023774-A1 | Pyridine analogs as C5A antagonists | C5AR1, C3AR1, C5AR2 | ADRA2A 479/4885ADRA2B 302/4885ADRA2C 423/4885 |
| US-20230312556-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | AHR, ARNT, NOTUM | ADRA2A 873/4885ADRA2B 1422/4885ADRA2C 1522/4885 |
| US-20230054782-A1 | BICYCLIC HETEROCYCLE COMPOUNDS METHODS OF USE THEREOF FOR THE TREATMENT OF HERPES VIRUSES | ZC3HAV1, HDAC11, CXCR1 | ADRA2A 4323/4885ADRA2B 4241/4885ADRA2C 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.